The U.S. government is pulling GlaxoSmithKline’s and Vir Technology’s investigational monoclonal antibody for COVID-19 from certain states where cases of the new subvariant of Omicron, BA.2, are high, as tests have shown that the treatment isn’t effective against the new strain. And the FDA has amended sotrovimab’s Emergency Use Authorization (EUA) accordingly.
Source: Drug Industry Daily